Azenta, Inc. (AZTA)
NASDAQ:AZTA
Top Page
Azenta
(NASDAQ:AZTA)
Select Model
Select Model
Rating:56Neutral
Price Target:
$21.00
▼(-25.48% Downside)
Action:ReiteratedDate:03/04/26
AZTA scores as a mid-range setup driven by strong financial flexibility (low leverage, substantial cash, and positive recent cash flow) and reaffirmed improvement targets, but weighed down by very weak technical momentum and ongoing profitability/margin pressures. Valuation is also less supportive due to losses (negative P/E) and no dividend yield provided.
Positive Factors
Balance sheet strength and liquidity
Extremely low leverage and a large cash reserve provide durable financial flexibility. This supports funding organic investments, M&A, share repurchases and weathering cyclical weakness without forced financing, reducing solvency risk and enabling multi-quarter strategic execution.
Negative Factors
Ongoing unprofitability and volatile results
Persistent operating losses and earnings volatility limit reinvestment capacity and shareholder returns. Continued negative net income increases reliance on cash reserves and execution to hit margin targets; failure to sustain improvement risks erosion of investor confidence and strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength and liquidity
Extremely low leverage and a large cash reserve provide durable financial flexibility. This supports funding organic investments, M&A, share repurchases and weathering cyclical weakness without forced financing, reducing solvency risk and enabling multi-quarter strategic execution.
Read all positive factors
Azenta (AZTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$941.96M
Dividend YieldN/A
Average Volume (3M)896.70K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue Growth-9.49%
EPS Growth58.97%
CountryUS
Employees3,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.09
Shares Outstanding46,061,527
10 Day Avg. Volume1,214,023
30 Day Avg. Volume896,701
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit2.79
Enterprise Value/Ebitda13.93
Forecast
1Y Price Target
$39.67Price Target Upside40.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.79
Revenue Forecast (FY)$618.57M
Azenta Business Overview & Revenue Model
Company Description
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences...
How the Company Makes Money
Azenta makes money primarily by selling life-sciences products and services used to store, manage, process, and analyze biological samples. A key revenue stream comes from its Sample Management Solutions activities, which include (1) selling autom...
Azenta Key Performance Indicators (KPIs)
Azenta Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Neutral
The call presents a balanced picture: management reaffirmed full-year guidance, highlighted strong cash, active capital allocation (including a $250M buyback authorization), and clear operational initiatives (ABS, Kaizen, regionalization) that support a planned margin and revenue ramp in the back half. However, near-term results show meaningful margin compression (gross margin down ~360 bps, adjusted EBITDA margin down ~230 bps), automated store quality remediation costs ($3M–$5M), North American softness and a meaningful decline in Sanger sequencing. Given the mix of strategic positives and notable near-term headwinds, the tone is cautiously optimistic but tempered by execution and macro risks.Positive Updates
Total Revenue and Organic Trend
Total revenue of $149 million for Q1 FY2026, up 1% reported and down ~1% organically with a ~2% foreign exchange headwind.
Negative Updates
Gross Margin Compression
Reported gross margin of 44.1% for the quarter, down ~360 basis points year-over-year, driven by underutilized lab capacity (lower North America volumes), regional mix, and rework costs.
Read all updates
Q1-2026 Updates
Positive
Negative
Total Revenue and Organic Trend
Total revenue of $149 million for Q1 FY2026, up 1% reported and down ~1% organically with a ~2% foreign exchange headwind.
Read all positive updates
Company Guidance
Azenta reaffirmed fiscal 2026 guidance of 3%–5% organic revenue growth and ~300 basis points of adjusted EBITDA margin expansion, forecasting Multiomics to deliver low‑single‑digit growth and Sample Management Solutions mid‑single‑digit growth with acceleration in the second half; the company noted Q1 results of $149M total revenue (up 1% reported, down 1% organic, -2% FX), non‑GAAP EPS $0.09, adjusted EBITDA $13M (8.5% margin, down ~230 bps), gross margin 44.1% (down 360 bps), free cash flow of $15M (including B Medical), cash and marketable securities of $571M (no debt), Q1 capex ~$6M, a $10M non‑cash loss on assets held for sale, and a $3–5M full‑year estimated impact from automated‑stores remediation expected to largely lapse after Q2; management expects the 300 bps of margin expansion to be driven roughly by ~200 bps of gross profit improvement (volume, ABS productivity, pricing) and ~100 bps from OpEx, expects >30% YoY free cash flow improvement, and has a $250M share repurchase authorization.Azenta Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 595.19M | 593.82M | 573.45M | 665.07M | 555.50M | 513.70M |
| Gross Profit | 269.63M | 270.28M | 254.62M | 233.26M | 230.62M | 214.51M |
| EBITDA | 53.93M | 54.07M | 71.62M | 55.15M | 48.35M | 9.94M |
| Net Income | -57.82M | -55.76M | -164.90M | -14.26M | -428.96M | 110.75M |
Balance Sheet | ||||||
| Total Assets | 2.07B | 2.06B | 2.10B | 2.89B | 3.72B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 412.05M | 340.92M | 462.09M | 1.02B | 1.57B | 227.51M |
| Total Debt | 108.92M | 111.17M | 70.68M | 60.44M | 49.23M | 94.77M |
| Total Liabilities | 359.60M | 330.70M | 331.07M | 351.22M | 352.74M | 494.18M |
| Stockholders Equity | 1.71B | 1.73B | 1.77B | 2.53B | 3.36B | 1.33B |
Cash Flow | ||||||
| Free Cash Flow | 30.93M | 38.32M | 12.35M | -33.60M | -543.48M | 97.05M |
| Operating Cash Flow | 63.23M | 72.18M | 49.74M | 5.83M | -466.05M | 149.86M |
| Investing Cash Flow | -130.78M | -90.46M | 224.74M | 431.38M | 1.47B | -146.35M |
| Financing Cash Flow | -7.10M | -9.59M | -659.21M | -840.46M | -62.76M | -25.91M |
Azenta Technical Analysis
Negative
28.18
Price Trends
29.98
Negative
31.79
Negative
31.38
Negative
Market Momentum
-2.52
Negative
31.63
Neutral
23.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Negative. The current price of 28.18 is above the 20-day moving average (MA) of 23.27, below the 50-day MA of 29.98, and below the 200-day MA of 31.38, indicating a bearish trend. The MACD of -2.52 indicates Negative momentum. The RSI at 31.63 is Neutral, neither overbought nor oversold. The STOCH value of 23.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTA.
Azenta Risk Analysis
Azenta disclosed 35 risk factors in its most recent earnings report. Azenta reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azenta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $951.51M | -95.19 | -3.40% | ― | -18.82% | 92.56% | |
60 Neutral | $1.47B | -165.01 | -2.43% | ― | 15.80% | 26.94% | |
56 Neutral | $941.96M | -24.75 | -3.39% | ― | -9.49% | 58.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $939.26M | -14.54 | -23.24% | ― | -32.42% | -540.37% | |
45 Neutral | $1.13B | -1.76 | -46.45% | ― | -3.43% | 38.98% | |
44 Neutral | $161.56M | -5.36 | -127.51% | ― | 30.55% | -340.19% |
* Healthcare Sector Average
AZTA
Azenta
21.31
-15.84
-42.64%
ATRC
Atricure
29.61
-5.24
-15.04%
QDEL
QuidelOrtho
16.17
-19.18
-54.26%
STAA
Staar Surgical
18.97
1.51
8.65%
BLFS
BioLife Solutions
19.70
-6.12
-23.70%
SMTI
Sanara MedTech
18.08
-13.12
-42.05%
Azenta Corporate Events
Business Operations and StrategyM&A Transactions
Azenta Acquires UK Biocentre to Expand European Biorepository
Positive
Mar 4, 2026
On March 4, 2026, Azenta announced that its subsidiary Azenta UK Ltd had completed the acquisition of UK Biocentre Limited, a UK-based provider of sample management, storage and high-throughput processing services, for total consideration of GBP 2...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Azenta Shareholders Reaffirm Board, Pay Plans and Auditor
Positive
Jan 29, 2026
At its annual meeting on January 28, 2026, Azenta, Inc. stockholders voted to re-elect all nominated directors, signaling continued support for the company’s current board composition and governance. Investors also backed, on an advisory bas...
Business Operations and StrategyM&A Transactions
Azenta divests B Medical Systems to streamline portfolio
Positive
Dec 29, 2025
On December 29, 2025, Azenta announced that its affiliate Azenta Germany GmbH has entered into a definitive agreement to sell the company’s Luxembourg-based B Medical Systems business, a global manufacturer and distributor of medical refrige...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.